New work is giving keto followers a sharper, more biological reason to care about ketones in the brain. The story is not that keto has been proven to treat multiple sclerosis, but that ketone metabolism now has a clearer foothold in the cells that protect myelin and axons, especially under inflammatory stress.
What MCT2 adds to the myelin story
The study centers on monocarboxylate transporter 2, or MCT2, a protein in oligodendrocytes, the glial cells that wrap axons in myelin and help keep white matter running smoothly. In progressive multiple sclerosis, the researchers found MCT2 was downregulated in oligodendrocytes, which puts a specific transporter at the intersection of white matter injury and disease biology.
That matters because white matter has long been hard to model metabolically. The paper frames the field’s big question plainly: the energy determinants of white matter integrity have been difficult to pin down. By tying MCT2 loss to disease-relevant pathology, the study gives that abstract question a concrete cellular target.
What happened when MCT2 was removed in mice
In the mouse work, deleting MCT2 in oligodendrocytes did not kill the cells. Instead, it disrupted what those cells were doing for the tissue around them. The deletion downregulated lipid-synthesis-associated enzymes and impaired myelin maintenance, showing that oligodendrocytes can survive while still failing at the job that keeps axons insulated and supported.
The axon side of the story was just as important. The model showed increased axonal lactate dehydrogenase A, a sign that axons were under metabolic strain, and the same model showed axonal injury. For keto readers, that is the kind of detail that makes the field feel familiar: when fuel handling is stressed, the issue is not just energy in the abstract, but whether vulnerable cells can keep up with the demand.
Why a ketogenic diet enters the conversation
This is where the ketogenic-diet angle becomes interesting. The authors report that the effects of MCT2 loss, including the axonal metabolic stress and injury, were alleviated by ketogenic diet exposure. In plain terms, the diet appears to have offered an alternate fuel pathway when the system’s usual metabolic support was compromised.
That does not make keto a stand-alone cure, and the study does not claim that. What it does suggest is mechanistic context: ketones may help brain-supporting cells and nearby axons cope when glucose-based energy handling is impaired. For a community that already thinks about ketosis as more than just weight loss, this is the kind of paper that connects everyday keto language to neural cell biology.
How this fits with MS diet research already underway
The new mechanism lands in a field that is already testing ketone-based eating patterns in multiple sclerosis. A 18-month randomized controlled study enrolled 105 people with relapsing-remitting multiple sclerosis, RRMS, and the ketogenic-diet arm used 20 to 40 grams of carbohydrates per day. That trial reported exploratory cognitive improvement at 18 months, which keeps the diet conversation alive without overstating it.
At the same time, the broader evidence base is still small. A 2025 review found only six MS ketogenic-diet studies published between 2017 and 2024, a reminder that the human literature remains limited even as interest grows. Researchers are looking at inflammation, fatigue, cognition, and quality of life, but the field is still building the kind of data that can separate hope from proof.
Why this paper matters to keto followers
The strongest value of this study is not a headline about treatment. It is the way it narrows the biology. The authors tie a specific transporter, MCT2, to a specific cell type, oligodendrocytes, and to a specific disease context, progressive multiple sclerosis. That gives ketone metabolism a more credible place in neurology, especially in white matter, where metabolic support and structural protection are tightly linked.
The collaboration behind the work also reflects how serious the topic has become, spanning centers at the University of the Basque Country and Achucarro in Leioa and Bilbao, CIBERNED and the University of Valencia in Madrid and Valencia, Sorbonne Université and the Paris Brain Institute in Paris, Mayo Clinic Jacksonville in Florida, and the University of Poitiers in France. This is not fringe speculation on the edge of the field. It is mainstream neuroscience asking whether ketone metabolism can buffer the exact cells that fail when white matter breaks down.
The takeaway for the keto world
For now, the cleanest reading is also the most responsible one: the study strengthens the case that ketones matter to brain health by showing how metabolic support helps oligodendrocytes preserve myelin and axonal integrity under stress. The leap from mouse mechanism to human therapy is still a long one, but the path is getting easier to see.
That is the real hook here. Keto is not being sold as a magic answer to multiple sclerosis. Instead, it is being placed inside a much more precise map of myelin maintenance, axonal support, and the cellular energy shifts that may one day matter for white matter disease.
Every story on Keto Diet Magazine is assembled by an automated editorial system that works from verified research, official records, and credible reporting, then clears automated accuracy and moderation checks before it goes live. The standards that system follows are set and overseen by the people who run the publication. Read our full editorial policy.
Know something we missed? Have a correction or additional information?
Submit a Tip
